

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



Proteins



Product Data Sheet

THK5351

Cat. No.: HY-101183 CAS No.: 1707147-26-9 Molecular Formula: C₁₈H₁₈FN₃O₂ Molecular Weight: 327.35

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 2 years

> -20°C 1 year

SOLVENT & SOLUBILITY

In Vitro

DMSO: 50 mg/mL (152.74 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	3.0548 mL	15.2742 mL	30.5483 mL
	5 mM	0.6110 mL	3.0548 mL	6.1097 mL
	10 mM	0.3055 mL	1.5274 mL	3.0548 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.64 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- β -CD in saline) Solubility: ≥ 2.5 mg/mL (7.64 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (7.64 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	THK5351 can be radiolabeled and used as a radiotracer for in vivo imaging of tau pathology in the brain.
In Vitro	Aggregated tau protein is a major neuropathological substrate central to the pathophysiology of neurodegenerative diseases such as Alzheimer's disease (AD). ¹⁸ F-THK5351 binds to Alzheimer disease hippocampal homogenates with high affinity (K _d =2.9 nM; maximum number of binding sites=368.3 pmol/g tissue). It has fast dissociation from white-matter tissue. The THK5351 binding amount correlates with the amount of tau deposits in tissue ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	$THK5351\ exhibits\ favorable\ pharmacokinetics\ and\ no\ defluor ination\ in\ mice.\ ^{18}F-THK5351\ enters\ the\ brain\ immediately$

after intravenous injection and shows a fast washout from the brain. At 0.1 and 1 mg/kg, no animals died and no treatment-related changes in any animal are noted in clinical observations, body weight measurement, and pathologic examination^[1]. Autoradiography in the brain sections of patients with PSP demonstrates [3 H]THK-5351 binding to tau deposits with a high selectivity. Although patients with PSP exhibits no remarkable [18 F]THK-5351 retention in the temporal cortex, significantly higher tracer retention is observed in the globus pallidus and midbrain^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com